Cozad Asset Management Inc. Sells 34 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cozad Asset Management Inc. trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,417 shares of the biopharmaceutical company’s stock after selling 34 shares during the quarter. Cozad Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,592,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. 83.31% of the stock is owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $816.65 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $90.03 billion, a P/E ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 12-month low of $783.57 and a 12-month high of $1,211.20. The firm has a 50-day moving average price of $1,035.92 and a two-hundred day moving average price of $1,038.36.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. TD Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,092.62.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.